Ariad Pharmaceuticals PT Lowered to $26.00 (ARIA)
Research analysts at Brean Capital cut their target price on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $28.00 to $26.00 in a report released on Monday, AR Network reports. The firm currently has a “buy” rating on the stock. Brean Capital’s target price indicates a potential upside of 41.30% from the company’s current price.
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) traded down 1.55% on Monday, hitting $18.40. The stock had a trading volume of 7,593,465 shares. Ariad Pharmaceuticals has a one year low of $15.35 and a one year high of $25.40. The stock’s 50-day moving average is $19.47 and its 200-day moving average is $18.64. The company’s market cap is $3.406 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter last year, the company posted ($0.31) earnings per share. Ariad Pharmaceuticals’s revenue was up 4302.5% compared to the same quarter last year. Analysts expect that Ariad Pharmaceuticals will post $-1.63 EPS for the current fiscal year.
A number of other firms have also recently commented on ARIA. Analysts at Maxim Group cut their price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $26.00 to $24.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Oppenheimer upgraded shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from a “market perform” rating to an “outperform” rating in a research note to investors on Monday. They now have a $24.00 price target on the stock, up previously from $23.00. Finally, analysts at BMO Capital Markets downgraded shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from an “outperform” rating to a “market perform” rating in a research note to investors on Monday. They now have a $21.00 price target on the stock, down previously from $37.00. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Ariad Pharmaceuticals has a consensus rating of “Buy” and an average target price of $26.72.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.